$17.18
-1.8%CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Chief Financial Officer
Compensation
$519,616
Chief People Officer
Chief Technology Officer
Compensation
$502,686
Co-Founder, Chief Medical Advisor & Director
Compensation
$201,363
Co-Founder, President, Chief Executive Officer & Director
Compensation
$805,296
General Counsel
Senior Vice President of Data Science
Senior Vice President of Marketing
Senior Vice President of Operations
Senior Vice President of Sales
During the last 12 months, insiders have purchased $86K and sold $8.19M worth of CBLL shares, resulting in $8.11M of net selling activity.
0
0.00
40.6K
747.46K
-747K
-$747K
3.0K
55.24K
263.9K
5.48M
-5.4M
-$5.43M
6.6K
31.09K
125.2K
1.96M
-1.9M
-$1.93M
0
0.00
0
0.00
+0
+$0
Woo Raymond
Officer: Chief Technology Officer
$86K
Chao Xingjuan
Director, Officer: President And Ceo
$4.29M
Parvizi Josef
Director
$2.12M
Burke William W
Director
$506K
Blumberg Scott
Officer: Chief Financial Officer
$455K
Woo Raymond
Officer: Chief Technology Officer
$442K
Strong bearish signal with $8.11M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
CBLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 02, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 29, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.